Methods of treating cancer

1. A method of treating NSCLC in an individual comprising administering to the individual a) an effective amount of a composition comprising nanoparticles comprising paclitaxel and an albumin and b) an effective amount of a platinum-based agent, wherein treatment is based upon the individual having squamous cellular carcinoma.

2. The method of claim 1 , wherein the method comprises selecting the individual for treatment based on the individual having squamous cellular carcinoma.

3. The method of claim 1 , wherein the effective amount of the composition comprising nanoparticles comprising paclitaxel and albumin is between about 50 mg/m 2 and about 125 mg/m 2 .

4. The method of claim 1 , wherein the composition comprising nanoparticles comprising paclitaxel and albumin is administered weekly.

5. The method of claim 1 , wherein the effective amount of the platinum-based agent is between about AUC=2 and about AUC=6.

6. The method of claim 1 , wherein the platinum-based agent is administered once every three weeks.

7. The method of claim 1 , wherein the effective amount of the composition comprising nanoparticles comprising paclitaxel and albumin is 100 mg/m 2 administered weekly and the effective amount of the platinum-based agent is AUC=6 administered once every three weeks.

8. The method of claim 1 , wherein paclitaxel in the nanoparticles is coated with albumin.

9. The method of claim 1 , wherein the nanoparticles in the composition have an average diameter of no greater than about 200 nm.

10. The method of claim 1 , wherein the NSCLC is Stage IIIB NSCLC or Stage IV NSCLC.

11. The method of claim 1 , wherein the composition comprising nanoparticles comprising paclitaxel and albumin and the platinum-based agent are administered parenterally.

12. The method of claim 11 , wherein the composition comprising nanoparticles comprising paclitaxel and albumin and the platinum-based agent are administered intravenously.

13. The method of claim 1 , wherein the platinum-based agent is carboplatin.

14. The method of claim 1 , wherein the individual is human.

15. The method of claim 1 , wherein the method further comprises the administration of thoracic radiation.

16. The method of claim 15 , wherein the effective amount of the composition comprising nanoparticles comprising paclitaxel and albumin is between about 20 mg/m 2 to about 60 mg/m 2 administered weekly, the effective amount of a platinum-based agent is between about AUC=2 to about AUC=6 administered weekly, and the thoracic radiation is between about 25 to about 40 fractions by either 3D conformal or intensity-modulated techniques concurrently.

17. The method of claim 1 , wherein the weight ratio of albumin and paclitaxel in the nanoparticle composition is about 1:1 to about 9:1.

18. The method of claim 17 , wherein the weight ratio of albumin and paclitaxel in the nanoparticle composition is about 9:1.

19. The method of claim 8 , wherein the weight ratio of albumin and paclitaxel in the nanoparticle composition is about 1:1 to about 9:1.

20. The method of claim 9 , wherein the weight ratio of albumin and paclitaxel in the nanoparticle composition is about 1:1 to about 9:1.

21. The method of claim 19 , wherein the nanoparticles in the composition have an average diameter of no greater than about 200 nm.

22. The method of claim 13 , wherein the weight ratio of albumin and paclitaxel in the nanoparticle composition is about 1:1 to about 9:1.

23. The method of claim 22 , wherein the weight ratio of albumin and paclitaxel in the nanoparticle composition is about 9:1.

24. The method of claim 22 , wherein paclitaxel in the nanoparticles is coated with the albumin.

25. The method of claim 24 , wherein the nanoparticles in the composition have an average diameter of no greater than about 200 nm.

26. The method of claim 23 , wherein paclitaxel in the nanoparticles is coated with the albumin.

27. The method of claim 26 , wherein the nanoparticles in the composition have an average diameter of no greater than about 200 nm.